Detailed information for compound 1990228

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 440.415 | Formula: C19H16F4N4O2S
  • H donors: 2 H acceptors: 4 LogP: 3.33 Rotable bonds: 6
    Rule of 5 violations (Lipinski): 1
  • SMILES: Nc1cnc(cn1)c1ccc(cc1F)c1ccccc1S(=O)(=O)NC(C(F)(F)F)C
  • InChi: 1S/C19H16F4N4O2S/c1-11(19(21,22)23)27-30(28,29)17-5-3-2-4-13(17)12-6-7-14(15(20)8-12)16-9-26-18(24)10-25-16/h2-11,27H,1H3,(H2,24,26)
  • InChiKey: MMJYJAOZVYCUHZ-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens arachidonate 5-lipoxygenase-activating protein Starlite/ChEMBL No references

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Trichomonas vaginalis STE family protein kinase 0.0224 0.0077 1
Loa Loa (eye worm) STE/STE7/MEK1 protein kinase 0.0224 0.0077 0.0077
Echinococcus multilocularis MAP kinase activated protein kinase 2 0.3244 1 1
Toxoplasma gondii CMGC kinase, MAPK family (ERK) MAPK-1 0.0201 0 0.5
Leishmania major mitogen-activated protein kinase kinase 5, putative;with=GeneDB:LmxM36.0860 0.0224 0.0077 1
Trypanosoma brucei mitogen-activated protein kinase kinase 5 0.0224 0.0077 1
Brugia malayi Dual specificity mitogen-activated protein kinase kinase mek-2 0.0224 0.0077 0.0077
Trypanosoma cruzi mitogen-activated protein kinase kinase 5 0.0224 0.0077 1
Loa Loa (eye worm) camk/mapkapk/mapkapk protein kinase 0.3244 1 1
Giardia lamblia Kinase, STE STE20 0.0224 0.0077 1
Echinococcus granulosus MAP kinase activated protein kinase 2 0.3244 1 1
Echinococcus multilocularis dual specificity mitogen activated protein 0.0224 0.0077 0.0077
Trichomonas vaginalis STE family protein kinase 0.0224 0.0077 1
Schistosoma mansoni protein kinase 0.0224 0.0077 0.0077
Schistosoma mansoni serine/threonine protein kinase 0.3244 1 1
Trichomonas vaginalis STE family protein kinase 0.0224 0.0077 1
Echinococcus granulosus dual specificity mitogen activated protein 0.0224 0.0077 0.0077

Activities

Activity type Activity value Assay description Source Reference
Ki (binding) = 1 nM BindingDB_Patents: Homogeneous Time Resolved Fluorescence Assay. The assay below is used to test the modulatory activity of compounds against FLAP. Human and mouse FLAP-encoding DNA was amplified by polymerase chain reaction and cloned into pFastBacl (Invitrogen) with a NH2-terminal 6-His tag for expression in Spodoptera frugiperda (Sf-9) cells. FLAP-containing membranes were prepared as was a FITC-labeled FLAP modulator [5-[({[2-(2-{3-[3-(tert-Butylsulfanyl)-1-(4-chlorobenzyl)-5-(quinolin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropanoyl}hydrazino)-2-oxoethyl]sulfanyl}acetyl)amino]-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid]. The FLAP binding assay is performed in HTRF format (homogeneous time resolved fluorescence). FLAP-containing membranes (1 ug/well final for human) are incubated in the presence of the HTRF ligand, [5-[({[2-(2-{3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(quinolin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropanoyl}hydrazino)-2-oxoethyl]sulfanyl}acetyl)amino]-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid]. ChEMBL. No reference

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

No literature references available for this target.

If you have references for this compound, please enter them in a user comment (below) or Contact us.